SLC5A2 and diabetes mellitus: A large meta-analysis documented that, independent of diabetes, SGLT2 inhibitors significantly reduce the risk of kidney disease progression by 37%, acute kidney injury by 23% and cardiovascular death or hospitalization for HF by 23% [9].